Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI® in combination with daratumumab achieved statistically significant improvements in progression-free and overall survival versus standard of care1 Pending approval, this novel complementary immunotherapy combination is positioned to delay disease progression for patients treated as early as second line, with 83% of patients alive at three years1
Source: Johnson & Johnson Press Releases
